Efficacy and safety of Tong-luo Qu-tong plaster for cervical spondylotic radiculopathy: study protocol for a randomized, double-blind, parallel positive controlled, multicenter clinical trial

Efficacy and safety of Tong-luo Qu-tong plaster for cervical spondylotic radiculopathy: study protocol for a randomized, double-blind, parallel positive controlled, multicenter clinical trial | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Study protocol Efficacy and safety of Tong-luo Qu-tong plaster for cervical spondylotic radiculopathy: study protocol for a randomized, double-blind, parallel positive controlled, multicenter clinical trial Hui Li, Xingwen Xie, Yongli Zhao, Minzhen Wang, Jianguo Li, Dingpeng Li, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-2253409/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background : Cervical spondylotic radiculopathy (CSR) is one of the most common diseases in clinic. Clinical symptoms such as neck pain and upper limb numbness are mainly caused by cervical degenerative changes and compression of cervical nerve roots. The incidence of CSR is the highest among all types of cervical spondylosis, accounting for about 60%~70%, seriously affecting the quality of life and work, causing huge economic negative to patients. Traditional Chinese medicine (TCM) has been definited efficacy and unique advantages in the treatment of CSR. Tongluo Qutong plaster (TLQT) is the most commonly used external drug in China in the treatment of CSR. It is effective for patients to improve neck pain, stiffness and numbness of both upper limbs, but there is a lack of high-quality clinical evidence to support it. The purpose of this study was to evaluate the efficacy and safety of TLQT in the treatment of CSR. Methods : This is a randomized, double-blind, parallel positive controlled, multi-center clinical trial. 240 patients who met the inclusion criteria were randomly divided into TLQT group and diclofenac sodium plaster group. The treatment period was 3 weeks. Follow-up will be conducted 12 weeks after intervention completion. The main observation index was visual analogue scale (VAS), and the secondary observation index was neck disability index (NDI) and TCM syndrome score. Safety observation indicators will include electrocardiogram, blood tests (including blood routine tests, liver and renal function), routine urine tests, and routine stool tests.The primary and secondary indicators will be performed at 0th, 3th, 7th, 21th and 84th day, and the safety indicators will be performed at 0th, 21th day. Conclusion : This study will provide evidence for the efficacy and safety of TLQT in treating CSR patients. Trial registration: This protocol has been registered in Chinese Clinical Trials Registry. Registration number: ChiCTR2200062271. Registered on 31 July 2022. Protocol randomized controlled tria cervical spondylotic radiculopathy Tongluo Qutong plaster diclofenac sodium plaster Figures Figure 1 1. Introduction Cervical spondylotic radiculopathy refers to the symptoms and signs due to the compression of the corresponding cervical nerve root by the degenerative changes of the cervical vertebra [ 1 , 2 ] . The characteristic symptoms of CSR are upper limb numbness or radiation pain along the nerve root control area, neck pain and stiffness are often the earliest symptoms. People with the disease are often see bad posture such as long-term desk work, motor vehicle drivers, long-time bow, which seriously affect people's life and work [ 3 , 4 ] . According to the relevant statistics, CSR mostly occurs in people aged 40 to 60 years old, the prevalence rate is 3.5 per 1000 people [ 5 ] . At present, the treatment of CSR is mainly divided into non-operative therapy and surgical therapy, of which non-operative therapy is the first choice and the most basic treatment of CSR, including head and neck traction, physiotherapy, exercise therapy, drug therapy, TCM therapy. When there is no myelopathy or obvious dysfunction, 75% of CSR patients can improve their symptoms after non-surgical treatment [ 6 ] . In clinical practice, common oral drugs such as nonsteroidal antiinflammatory drugs(NSAIDs) and nutritional nerve drugs often have adverse reactions such as digestive system and kidney damage while giving their therapeutic advantages [ 7 ] . Therefore, it is of great significance for CSR patients to find a safe and effective treatment. In recent years, many traditional Chinese herbal medicines are effective in the treatment of related musculoskeletal diseases [ 8 ] . Sticking therapy is under the guidance of the basic theory of TCM, the application of Chinese herbal medicine preparation, sticked to the skin, acupoints, local lesions and other parts, belongs to the external treatment of TCM. Sticking therapy is an important part of external therapy of TCM, and it is easier to operate, safer to use, less side effect and acceptable to patients than oral drugs. TLQT as a traditional Chinese patent preparation, is an officially approved patch for the treatment of CSR in China. However, its efficacy and safety have not been reported in a large sample of clinical literature. The purpose of this study is to evaluate the efficacy and safety of TLQT in the treatment of CSR. 2. Methods 2.1 Study design This study is a prospective, multi-center, randomized, double-blind, parallel control of positive drugs clinical trial and it will be carried out in four hospitals, including the Second People's Hospital of Gansu Province, Gansu Provincial Hospital of TCM, the Affiliated Hospital of Gansu University of TCM and Tianshui Hospital of TCM. The 240 eligible participants will be assigned to 1 of 2 groups with a 1:1 ratio. The control group will receive diclofenac sodium plaster , and the experimental group will receive TLQT treatment. The study period will include 3 week-treatment phase and 12 week-follow-up. The study design flowchart is as shown in Figure 1. 2.2. Ethic approval This experiment was approved by the ethics committee of four hospitals, including the second people's Hospital of Gansu Province(approval number: GSSEY2021-YW010-02). The design and implementation of this study should follow the principles of the Helsinki Declaration of the World Medical Congress. The rights and safety of the participants are the primary factors considered in this study, and are higher than the consideration of scientific and social benefits. We will provide free drugs to patients in the experimental group and the control group. Besides, we will keep the basic information strictly confidential. 2.3. Participants We will make promotional posters in the orthopedic outpatient areas of four hospitals or release information through social media of hospital to recruit 240 CSR participants.The investigator will introduce the study protocol (study objective, procedure and time commitment, potential risks and benefits related to the study) to potential subjects in detail, and obtain written informed consent. The following eligibility criteria apply to all patients enrolled in the study. 2.3. 1. Inclusion criteria In line with the diagnostic criteria of western medicine for CSR; The main clinical manifestations were neck and /or shoulder and back pain, the VAS score of single site pain was≥4; The history of CSR is less than 5 years, and this attack of CSR is less than 1 week. Aged between 18 and 65 years, male or female; Junior high school education or above, more than 1 year experience in using smartphone; The participants informed consent and signed the relevant documents. 2.3. 2. Exclusion criteria: Cervical spondylosis with cervical type, spinal cord type, vertebral artery type and sympathetic type, previous X-ray/CT/MRI examination showed that the history of cervical spondylosis was more than 5 years. Patients with other upper limb pain, such as neck sprain, thoracic outlet syndrome, tennis elbow, carpal tunnel syndrome, scapulohumeral periarthritis, rheumatic myofibrositis, long head tenosynovitis of biceps brachii. Those who had received systematic treatment of CSR within 1 week, or who were using analgesics, NSAIDs, antidepressants or quinolones before entering the group; Patients who have undergone cervical surgery: cervical fracture, congenital deformity of cervical vertebra, bony stenosis of cervical canal, periradiculitis, tumor, tuberculosis and other diseases; The liver function exceeds the upper limit of the normal value by 1.5 times, and the renal function exceeds the upper limit of the normal value; Patients with severe primary cardiovascular disease, liver disease, kidney disease, hematological disease, lung disease or serious disease affecting their survival; Patients with applicable symptoms of cervical spondylosis(including:1. Systematic non-operative treatment is ineffective for more than 3-6 months, or occurs repeatedly and the symptoms seriously affect normal life or works; 2. Progressive atrophy of the innervated muscles due to nerve root lesions; 3. Those who have obvious nerve root tingling symptoms, acute severe pain, seriously affect sleep and normal life, or plan to undergo surgical treatment); Patients with damaged neck or abnormal skin , allergic skin; Women who prepare for pregnancy during lactation, pregnancy within half a year; Those who have drug patch matrix, history of drug allergy, allergic constitution, asthma, urticaria or allergic reactions induced by aspirin or other non-steroidal anti-inflammatory drugs in the past; The consultation showed that those who had participated in other clinical trials within 3 months; There are situations that the researchers think are not suitable to participate in the study, such as those with a long history of drinking. 2.3 Research interventions 2.3.1 Experimental group The experimental group will be treated with TLQT: 2 patches at a time, once a day, to cover the related cervical nerve roots, the application time was 10-12 hours each time.The treatment should not exceed 21 days. The drug is produced by Henan Lingrui Pharmaceutical Company, the production batch number is 210612. It is valid until May 2024. 2.3.2 Control group The patients in the control group will be treated with diclofenac sodium plaster: 2 patches at a time, once a day, to cover the related cervical nerve roots, and the application time was 10-12 hours each time.The intervention should not exceed 21 days. The drug is produced by Tongren Society in Japan, provided by Henan Lingrui Pharmaceutical Company, the production batch number is 210020, and the period of validity is until December 2023. 2.4. Sample size calculation Literature shows that [9] diclofenac sodium oral preparation after 7 days of treatment of CSR, its VAS scale decreased by 1.41. According to the estimation of the previous research results and the experience of clinical experts, the VAS score of TLQT decreased by about 1.80 after 7 days of treatment. Using the effectiveness test, the type I error probability is generally set to 0.025 on one side, the type II error probability is set to not more than 0.20, the standard deviation is assumed to be 30% of the therapeutic effect (0.423 in the control group and 0.54 in the experimental group). The sample size is calculated by PASS11.0, the calculated results were 26 cases in the test group and 26 cases in the control group. Considering the need of renewal of TCM varieties, the sample size was preset 200 cases, 100 cases in the experimental group and 100 cases in the control group. In addition, considering the withdrawal rate of no more than 20% in clinical trials and the maneuverability of clinical trials, the sample size of this trial was determined to be 120 cases in each group, a total of 240 cases. 2.5. Randomization and allocation concealment The random allocation scheme is generated by SAS9.4 software, the participants will be assigned to different intervention groups according to the randomized allocation scheme. Unique random coding of participants will be used in the study to ensure that all clinical research data of each subject were traceable. The random allocation scheme consisted of two parts: the first part lists the corresponding research groups of each random code, including group A and group B; the second part lists the corresponding research groups of group A and group B, such as the experimental group and the control group. After the researchers engaged in diagnosis and treatment register the information of the participants through the internet and confirm their membership in the group, they can obtain the random code of the subjects, in addition, the drug code of the participants is the same as the random code. 2.6. Blinding This study adopted the blind design of researchers and participants. In drug preparation, the appearance of the two groups' drugs were consistent before and after application, the taste of the two groups of drugs were similar. Drugs are numbered according to the random order of the trial, the researchers are responsible for networked random application, diagnosis, treatment, evaluation, and subject management through random coding. Researchers should avoid communicating with participants that may contain grouping information throughout the study. In order to ensure the objectivity of evaluation, data audit and data set partition, the researchers could not access the grouping information of the participants throughout the study. Each subject obtains a random code through the network (the drug code is the same as the random code). The grouping information of the participants is hidden before the researchers obtain it according to the process, the researchers who carry out diagnosis, treatment and evaluation can not know the grouping information of a certain participant before uncovering the blindness. The drug administrator is responsible for the storage, receipt, return, distribution and recovery of drugs, as well as the training and registration of first drug application. The written information of drug groups should not be kept in the information records of drug administrators, the research drugs and recycled drugs should be locked on the counter. Throughout the study, drug administrators were prohibited from communicating the grouping information of the participants with the researchers responsible for diagnosis, treatment, evaluation. 2.7. Discontinuation criteria 1. Situation in which the researcher believes that it is not appropriate for the participators to continue in the study. 2. Participants have the right to withdraw from the study at any stage without discrimination or retaliation, their rights and interests will not be affected. While respecting the individual rights of the participants, researchers should try their best to understand the reasons for their withdrawal in order to support better protection of the participants. 3. Patients with adverse events such as pregnancy should not continue to receive treatment. 2.8. Outcomes 2.8.1. Primary outcomes Pain is the most important clinical manifestation of CSR patients. VAS [10] will be used to evaluate pain changes in patients, and VAS is usually used to measure pain intensity [11] . patients will be asked to rate between 0 and 100, with 100 representing the greatest pain (far right) and 0 representing no pain (far left). 2.8.2. Secondary outcomes The neck dysfunction index [12] is one of the most commonly used indexes to evaluate the neck dysfunction of CSR patients. The NDI score included 4 subjective symptoms (neck pain intensity, headache, attention, sleep) and 6 items related to daily life activities (weightlifting, work, driving or cycling, entertainment, personal care, reading). In addition, TCM syndrome score was also the secondary outcomes. 2.8.3. Safety evaluation index The main safety indicators include routine blood, urine and stool, liver and kidney function, electrocardiogram and local skin irritation, and adverse events and adverse reactions during treatment. 2.9. Complications and adverse events during and after treatment During the clinical study, researchers should truthfully fill in the adverse event, including the occurrence time, severity, duration, measures taken and outcome of the adverse events. For the participants with adverse events related to the study, including abnormal laboratory results of clinical significance, the researchers and the medical institutions they worked for should ensure that the participants receive proper medical treatment and truthful information the of the relevant situations. at the same time, researchers should be vigilant on whether the participants have other diseases. 2.10. Data collection and management In this study, the data acquisition process depends on the electronic acquisition system. In the course of the study, researchers or participants can login the collection system through different ways. The required data will be collected according to the following case data collection schedule (Table 1). The participants mainly recorde the information of occupation/life characteristics, clinical symptoms, VAS and NDI data. The relevant data will be reviewed by the researchers and included in the medical records of the study. Since the risk is minimal, a formal data monitoring committee will not be required. Independent investigators will monitor data on a regular basis. 2.11. Statistical analysis Statistical analysis will use the statistical analysis software SAS9.4 for analysis and calculation. All statistical tests use two-sided test, the difference tested by P≤0.05 is statistically significant, the confidence interval is 95% credibility. The measurement data of different treatment groups will be statistically described by mean, standard deviation, median, minimum and maximum. The counting data of different treatment groups were statistically described by frequency (constituent ratio or incidence). In this study, the main efficacy index VAS score and secondary efficacy index NDI score are measurement data. In general, independent sample t-test is used for comparison between groups. If it does not satisfy the homogeneity of variance, independent sample corrected t-test is used. If it does not obey normal distribution, Wilcoxon rank sum test is used. At the same time, the covariance method is used to remove the confounding factors. The main efficacy analysis was based on FAS and the results of PPS analysis were provided. 3. Results The results of this trial will be published on the website of the China Clinical trial Registration Center and academic journals. 4. Discussion In recent years, with the change of life style and work patterns, the incidence of CSR is getting higher and higher. according to incomplete statistics, the global incidence rate is about 4.9%, the pain caused by the disease has also brought an indirect economic burden about $335 billion to the society [13] . Modern medicine has described the pathogenesis of CSR in terms of anatomy and pathology. At present, it is generally believed that protrusion of nucleus pulposus, displacement of adjacent joints, hyperplasia of uncinate process joints and changes in physiological curvature of cervical vertebrae are the common causes of CSR [14] .These factors can lead to nerve root stimulation and compression, causing circulatory disorders and inflammatory reactions around the cervical vertebra, resulting in a series of root symptoms. Because CSR does not pose a threat to patients' lives,in addition, middle-aged patients are under great pressure in life, work and society, it is not easy to pay enough attention to it in the early stage, long-term neck stiffness, adverse activity and pain not only bring physical pain to patients, but also easily cause certain negative effects on patients' psychology, such as anxiety, depression and other bad emotions, which directly affect the quality of life of patients. TLQT is mainly made of 11 traditional Chinese medicines such as cloves, pepper, cinnamon, dried ginger, plus borneol, camphor and menthol. It has the effects of promoting blood circulation and dredging collaterals, dispelling cold and dehumidification, reducing swelling and relieving pain. It is one of the traditional methods of TCM in the treatment of chronic musculoskeletal diseases. In the past ten years, TLQT has been widely used in the treatment of cervical spondylosis, especially CSR. This kind of treatment is convenient, low-cost, and is deeply loved by the majority of CSR patients. However, so far there is no high-quality clinical evidence to support the claimed efficacy of TLQT in relieving pain and numbness in CSR patients. Therefore, the purpose of this clinical trial is to evaluate the efficacy and safety of TLQT in the treatment of CSR. Abbreviations TLQT=Tongluo Qutong plaster, CSR=cervical spondylotic radiculopathy, TCM=traditional Chinese medicine, VAS=visual analogue scale, NDI=neck disability index; NSAIDs=onsteroidal antiinflammatory drugs Declarations Ethics approval and consent to participate This trial was approved by the Ethics Committee of the second people's Hospital of Gansu Province(number GSSEY2021-YW010-02), and all participants voluntarily provided signed informed consent. Consent for publication Not applicable. Availability of data and materials Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. Competing interests The authors declare that they have no competing interests. Funding This work was supported by the National Natural Science Foundation of China (81860864, 82160911, and 82174412), Gansu Province Top Talent training and support Fund Project ([2021]02). Authors' contributions Conceptualization: Hui Li, Yongli ZHAO Data curation: Hui Li, Yongli ZHAO Formal analysis: Minzhen Wang, Jianguo Li Investigation: Demin Lin, Jianguo Li, Dingpeng Li Methodology: Hui Li, Xingwen Xie Project administration: Xingwen Xie,Ning Li Writing - original draft: Hui Li, Xingwen Xie, Yongli ZHAO Writing - review and editing: Xingwen Xie, Ning Li Acknowledgements The authors have no conflicts of interest to disclose. References Lin T, Wang Z, Chen G, et al. Predictive Effect of Cervical Sagittal Parameters on Conservative Treatment of Single-Segment Cervical Spondylotic Radiculopathy. World Neurosurg. 2020;134:e1028-e1036. Hirai S, Kato S, Nakajima K, et al. Anatomical study of cervical intervertebral foramen in patients with cervical spondylotic radiculopathy. J Orthop Sci. 2021;26(1):86-91. Dai W, Wang X, Xie R, et al. Baduanjin exercise for cervical spondylotic radiculopathy: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(18):e0037s. Wang P, Zuo G, Du SQ, et al. Meta-analysis of the therapeutic effect of acupuncture and chiropractic on cervical spondylosis radiculopathy: A systematic review and meta-analysis protocol. Medicine (Baltimore). 2020;99(5):e18851. Yang F, Li WX, Liu Z, et al. Balance chiropractic therapy for cervical spondylotic radiculopathy: study protocol for a randomized controlled trial. Trials. 2016;17(1):513. Childress MA, Becker BA. Nonoperative Management of Cervical Radiculopathy. Am Fam Physician. 2016;93(9):746-54. Kartha S, Weisshaar CL, Philips BH, et al. Pre-treatment with Meloxicam Prevents the Spinal Inflammation and Oxidative Stress in DRG Neurons that Accompany Painful Cervical Radiculopathy. Neuroscience. 2018;388:393-404. Ding X, Wu J, Shen Q, et al. Clinical control study of traditional Chinese medicine hot compress combined with traction in the treatment of cervical spondylotic radiculopathy: Study protocol. Medicine (Baltimore). 2021;100(4):e23880. JIANG J C，WU J H，SHI C，et al.Clinical observation of Shi’s Tanyu Tongluo Decoction in the treatment of cervical spondylotic radiculopathy. Shanghai Journal of Traditional Chinese Medicine,2017;51(04):70-72. Joyce CR, Zutshi DW, Hrubes V,et al. Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol. 1975;8(6):415-20. Price DD, McGrath PA, Rafii A, et al. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17(1):45-56. Sterling M, Rebbeck T. The Neck Disability Index (NDI). Aust J Physiother. 2005;51(4):271. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715-24. Truumees E, Herkowitz HN. Cervical spondylotic myelopathy and radiculopathy. Instr Course Lect. 2000;49:339-60. Table 1 Table 1 The schedule of enrolment, interventions, and assessments Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-2253409","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Study protocol","associatedPublications":[],"authors":[{"id":173694241,"identity":"ec9eb657-f232-4c17-a43f-ff3531d55ea3","order_by":0,"name":"Hui Li","email":"","orcid":"","institution":"Gansu University of Chinese Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Hui","middleName":"","lastName":"Li","suffix":""},{"id":173694245,"identity":"e75c7ad9-d7c3-476f-8974-0719e8f75144","order_by":1,"name":"Xingwen Xie","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA2ElEQVRIiWNgGAWjYBACfvbGBoMPFTb19sebDxCnRbLncEPhjDNpCQxnjiUQp8XgRnrDZ96WQwkMN3wMiHTZgcTGjTMbDuQxzuD5eOMNg52cbgMBHYwNB5sNPu64U8ws3bvZcg5DsrHZAQJamBkb2wxnnnnG2CZzdps0D9DSbYS0sDEztv/mbTvM2COR84w4LTxsjA3GQC2JMyRy2IjTIsHD2GAIDGRjA55jxpZzDIjwi/395w9AUSlnwN788MabCjs5glrQrCQ2apC0kKpjFIyCUTAKRgQAAEhjSysfrhw9AAAAAElFTkSuQmCC","orcid":"","institution":"The Affiliated Hospital of Gansu University of Chinese Medicine","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Xingwen","middleName":"","lastName":"Xie","suffix":""},{"id":173694246,"identity":"0e5c40c8-6448-495d-90df-4ecfd7c8af0d","order_by":2,"name":"Yongli Zhao","email":"","orcid":"","institution":"The Affiliated Hospital of Gansu University of Chinese Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yongli","middleName":"","lastName":"Zhao","suffix":""},{"id":173694253,"identity":"0a74b9c7-4da2-4ade-b377-e20f5d2f6702","order_by":3,"name":"Minzhen Wang","email":"","orcid":"","institution":"Lanzhou University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Minzhen","middleName":"","lastName":"Wang","suffix":""},{"id":173694256,"identity":"a26ef4c8-0ac6-436e-b3c4-778029296f05","order_by":4,"name":"Jianguo Li","email":"","orcid":"","institution":"The Second People's Hospital of Gansu Province","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jianguo","middleName":"","lastName":"Li","suffix":""},{"id":173694257,"identity":"433c89fd-c921-46b0-9a30-736518d95590","order_by":5,"name":"Dingpeng Li","email":"","orcid":"","institution":"The Second People's Hospital of Gansu Province","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Dingpeng","middleName":"","lastName":"Li","suffix":""},{"id":173694259,"identity":"8a0f1653-573a-43ba-957b-3e0ec9d40c28","order_by":6,"name":"Ning Li","email":"","orcid":"","institution":"Gansu University of Chinese Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ning","middleName":"","lastName":"Li","suffix":""}],"badges":[],"createdAt":"2022-11-09 03:44:18","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-2253409/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-2253409/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":32600664,"identity":"5966701f-aade-4c2c-a3f2-fcf4118cf752","added_by":"auto","created_at":"2023-02-07 15:52:46","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":142068,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eStudy flow diagram of trial participation\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure1..png","url":"https://assets-eu.researchsquare.com/files/rs-2253409/v1/cd3aa462d7f816d89d994a4e.png"},{"id":32989724,"identity":"c0e31085-a1d4-4f37-870a-ac8930f98739","added_by":"auto","created_at":"2023-02-15 15:59:27","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":680638,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-2253409/v1/5deeae7e-ba2a-4a3d-a1a8-4a7c86e049a8.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Efficacy and safety of Tong-luo Qu-tong plaster for cervical spondylotic radiculopathy: study protocol for a randomized, double-blind, parallel positive controlled, multicenter clinical trial","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eCervical spondylotic radiculopathy refers to the symptoms and signs due to the compression of the corresponding cervical nerve root by the degenerative changes of the cervical vertebra\u003csup\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]\u003c/sup\u003e. The characteristic symptoms of CSR are upper limb numbness or radiation pain along the nerve root control area, neck pain and stiffness are often the earliest symptoms. People with the disease are often see bad posture such as long-term desk work, motor vehicle drivers, long-time bow, which seriously affect people's life and work\u003csup\u003e[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]\u003c/sup\u003e. According to the relevant statistics, CSR mostly occurs in people aged 40 to 60 years old, the prevalence rate is 3.5 per 1000 people\u003csup\u003e[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]\u003c/sup\u003e. At present, the treatment of CSR is mainly divided into non-operative therapy and surgical therapy, of which non-operative therapy is the first choice and the most basic treatment of CSR, including head and neck traction, physiotherapy, exercise therapy, drug therapy, TCM therapy. When there is no myelopathy or obvious dysfunction, 75% of CSR patients can improve their symptoms after non-surgical treatment\u003csup\u003e[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]\u003c/sup\u003e. In clinical practice, common oral drugs such as nonsteroidal antiinflammatory drugs(NSAIDs) and nutritional nerve drugs often have adverse reactions such as digestive system and kidney damage while giving their therapeutic advantages\u003csup\u003e[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]\u003c/sup\u003e. Therefore, it is of great significance for CSR patients to find a safe and effective treatment.\u003c/p\u003e \u003cp\u003eIn recent years, many traditional Chinese herbal medicines are effective in the treatment of related musculoskeletal diseases\u003csup\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/sup\u003e. Sticking therapy is under the guidance of the basic theory of TCM, the application of Chinese herbal medicine preparation, sticked to the skin, acupoints, local lesions and other parts, belongs to the external treatment of TCM. Sticking therapy is an important part of external therapy of TCM, and it is easier to operate, safer to use, less side effect and acceptable to patients than oral drugs. TLQT as a traditional Chinese patent preparation, is an officially approved patch for the treatment of CSR in China. However, its efficacy and safety have not been reported in a large sample of clinical literature. The purpose of this study is to evaluate the efficacy and safety of TLQT in the treatment of CSR.\u003c/p\u003e"},{"header":"2. Methods","content":"\u003cp\u003e\u003cstrong\u003e2.1 Study design\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study is a prospective, multi-center, randomized, double-blind, parallel control of positive drugs clinical trial and it will be carried out in four hospitals, including the Second People\u0026apos;s Hospital of Gansu Province, Gansu Provincial Hospital of TCM, the Affiliated Hospital of Gansu University of TCM and Tianshui Hospital of TCM. The 240 eligible participants will be assigned to 1 of 2 groups with a 1:1 ratio. The control group will receive diclofenac sodium plaster , and the experimental group will receive TLQT treatment. The study period will include 3 week-treatment phase and 12 week-follow-up. The study design flowchart is as shown in Figure 1.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.2. Ethic approval\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis experiment was approved by the ethics committee of four hospitals, including the second people\u0026apos;s Hospital of Gansu Province(approval number: GSSEY2021-YW010-02). The design and implementation of this study should follow the principles of the Helsinki Declaration of the World Medical Congress. The rights and safety of the participants are the primary factors considered in this study, and are higher than the consideration of scientific and social benefits. We will provide free drugs to patients in the experimental group and the control group. Besides, we will keep the basic information strictly confidential.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.3. Participants\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe will make promotional posters in the orthopedic outpatient areas of four hospitals or release information through social media of hospital to recruit 240 CSR participants.The investigator will introduce the study protocol (study objective, procedure and time commitment, potential risks and benefits related to the study) to potential subjects in detail, and obtain written informed consent. The following eligibility criteria apply to all patients enrolled in the study.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.3. 1.\u0026nbsp;\u003c/strong\u003eInclusion criteria\u003c/p\u003e\n\u003col class=\"decimal_type\"\u003e\n \u003cli\u003eIn line with the diagnostic criteria of western medicine for CSR;\u003c/li\u003e\n \u003cli\u003eThe main clinical manifestations were neck and /or shoulder and back pain, the VAS score of single site pain was\u0026ge;4;\u003c/li\u003e\n \u003cli\u003eThe history of CSR is less than 5 years, and this attack of CSR is less than 1 week. \u0026nbsp;\u003c/li\u003e\n \u003cli\u003eAged between 18 and 65 years, male or female;\u003c/li\u003e\n \u003cli\u003eJunior high school education or above, more than 1 year experience in using smartphone;\u003c/li\u003e\n \u003cli\u003eThe participants informed consent and signed the relevant documents.\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u003cstrong\u003e2.3. 2.\u0026nbsp;\u003c/strong\u003eExclusion criteria:\u003c/p\u003e\n\u003col class=\"decimal_type\"\u003e\n \u003cli\u003eCervical spondylosis with cervical type, spinal cord type, vertebral artery type and sympathetic type, previous X-ray/CT/MRI examination showed that the history of cervical spondylosis was more than 5 years.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003ePatients with other upper limb pain, such as neck sprain, thoracic outlet syndrome, tennis elbow, carpal tunnel syndrome, scapulohumeral periarthritis, rheumatic myofibrositis, long head tenosynovitis of biceps brachii.\u003c/li\u003e\n \u003cli\u003eThose who had received systematic treatment of CSR within 1 week, or who were using analgesics, NSAIDs, antidepressants or quinolones before entering the group;\u0026nbsp;\u003c/li\u003e\n \u003cli\u003ePatients who have undergone cervical surgery: cervical fracture, congenital deformity of cervical vertebra, bony stenosis of cervical canal, periradiculitis, tumor, tuberculosis and other diseases;\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eThe liver function exceeds the upper limit of the normal value by 1.5 times, and the renal function exceeds the upper limit of the normal value;\u003c/li\u003e\n \u003cli\u003ePatients with severe primary cardiovascular disease, liver disease, kidney disease, hematological disease, lung disease or serious disease affecting their survival;\u003c/li\u003e\n \u003cli\u003ePatients with applicable symptoms of cervical spondylosis(including:1. Systematic non-operative treatment is ineffective for more than 3-6 months, or occurs repeatedly and the symptoms seriously affect normal life or works; 2. Progressive atrophy of the innervated muscles due to nerve root lesions; 3. Those who have obvious nerve root tingling symptoms, acute severe pain, seriously affect sleep and normal life, or plan to undergo surgical treatment);\u003c/li\u003e\n \u003cli\u003ePatients with damaged neck or abnormal skin , allergic skin;\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eWomen who prepare for pregnancy during lactation, pregnancy within half a year;\u003c/li\u003e\n \u003cli\u003eThose who have drug patch matrix, history of drug allergy, allergic constitution, asthma, urticaria or allergic reactions induced by aspirin or other non-steroidal anti-inflammatory drugs in the past;\u003c/li\u003e\n \u003cli\u003eThe consultation showed that those who had participated in other clinical trials within 3 months;\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eThere are situations that the researchers think are not suitable to participate in the study, such as those with a long history of drinking.\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u003cstrong\u003e2.3 Research interventions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.3.1 Experimental group\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe experimental group will be treated with TLQT: 2 patches at a time, once a day, to cover the related cervical nerve roots, the application time was 10-12 hours each time.The treatment should not exceed 21 days. The drug is produced by Henan Lingrui Pharmaceutical Company, the production batch number is 210612. It is valid until May 2024.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.3.2 Control group\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe patients in the control group will be treated with diclofenac sodium plaster: 2 patches at a time, once a day, to cover the related cervical nerve roots, and the application time was 10-12 hours each time.The intervention should not exceed 21 days. The drug is produced by Tongren Society in Japan, provided by Henan Lingrui Pharmaceutical Company, the production batch number is 210020, and the period of validity is until December 2023.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.4. Sample size calculation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eLiterature shows that\u003csup\u003e[9]\u003c/sup\u003e\u003csup\u003e\u0026nbsp;\u003c/sup\u003ediclofenac sodium oral preparation after 7 days of treatment of CSR, its VAS scale decreased by 1.41. According to the estimation of the previous research results and the experience of clinical experts, the VAS score of TLQT decreased by about 1.80 after 7 days of treatment. Using the effectiveness test, the type I error probability is generally set to 0.025 on one side, the type II error probability is set to not more than 0.20, the standard deviation is assumed to be 30% of the therapeutic effect (0.423 in the control group and 0.54 in the experimental group). The sample size is calculated by PASS11.0, the calculated results were 26 cases in the test group and 26 cases in the control group. Considering the need of renewal of TCM varieties, the sample size was preset 200 cases, 100 cases in the experimental group and 100 cases in the control group. In addition, considering the withdrawal rate of no more than 20% in clinical trials and the maneuverability of clinical trials, the sample size of this trial was determined to be 120 cases in each group, a total of 240 cases.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.5. Randomization and allocation concealment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe random allocation scheme is generated by SAS9.4 software, the participants will be assigned to different intervention groups according to the randomized allocation scheme. Unique random coding of participants will be used in the study to ensure that all clinical research data of each subject were traceable. The random allocation scheme consisted of two parts: the first part lists the corresponding research groups of each random code, including group A and group B; the second part lists the corresponding research groups of group A and group B, such as the experimental group and the control group. After the researchers engaged in diagnosis and treatment register the information of the participants through the internet and confirm their membership in the group, they can obtain the random code of the subjects, in addition, the drug code of the participants is the same as the random code.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.6. Blinding \u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study adopted the blind design of researchers and participants. In drug preparation, the appearance of the two groups\u0026apos; drugs were consistent before and after application, the taste of the two groups of drugs were similar. Drugs are numbered according to the random order of the trial, the researchers are responsible for networked random application, diagnosis, treatment, evaluation, and subject management through random coding. Researchers should avoid communicating with participants that may contain grouping information throughout the study. In order to ensure the objectivity of evaluation, data audit and data set partition, the researchers could not access the grouping information of the participants throughout the study. Each subject obtains a random code through the network (the drug code is the same as the random code). The grouping information of the participants is hidden before the researchers obtain it according to the process, the researchers who carry out diagnosis, treatment and evaluation can not know the grouping information of a certain participant before uncovering the blindness. The drug administrator is responsible for the storage, receipt, return, distribution and recovery of drugs, as well as the training and registration of first drug application. The written information of drug groups should not be kept in the information records of drug administrators, the research drugs and recycled drugs should be locked on the counter. Throughout the study, drug administrators were prohibited from communicating the grouping information of the participants with the researchers responsible for diagnosis, treatment, evaluation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.7. Discontinuation criteria\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e1. Situation in which the researcher believes that it is not appropriate for the participators to continue in the study.\u003c/p\u003e\n\u003cp\u003e2. Participants have the right to withdraw from the study at any stage without discrimination or retaliation, their rights and interests will not be affected. While respecting the individual rights of the participants, researchers should try their best to understand the reasons for their withdrawal in order to support better protection of the participants.\u003c/p\u003e\n\u003cp\u003e3. Patients with adverse events such as pregnancy should not continue to receive treatment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.8. Outcomes\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.8.1. Primary outcomes\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePain is the most important clinical manifestation of CSR patients. VAS\u003csup\u003e[10]\u003c/sup\u003e will be used to evaluate pain changes in patients, and VAS is usually used to measure pain intensity\u003csup\u003e[11]\u003c/sup\u003e. patients will be asked to rate between 0 and 100, with 100 representing the greatest pain (far right) and 0 representing no pain (far left).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.8.2. Secondary outcomes\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe neck dysfunction index\u003csup\u003e[12]\u003c/sup\u003e is one of the most commonly used indexes to evaluate the neck dysfunction of CSR patients. The NDI score included 4 subjective symptoms (neck pain intensity, headache, attention, sleep) and 6 items related to daily life activities (weightlifting, work, driving or cycling, entertainment, personal care, reading). In addition, TCM syndrome score was also the secondary outcomes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.8.3. Safety evaluation index\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe main safety indicators include routine blood, urine and stool, liver and kidney function, electrocardiogram and local skin irritation, and adverse events and adverse reactions during treatment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.9. Complications and adverse events during and after treatment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDuring the clinical study, researchers should truthfully fill in the adverse event, including the occurrence time, severity, duration, measures taken and outcome of the adverse events. For the participants with adverse events related to the study, including abnormal laboratory results of clinical significance, the researchers and the medical institutions they worked for should ensure that the participants receive proper medical treatment and truthful information the of the relevant situations. at the same time, researchers should be vigilant on whether the participants have other diseases.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.10. Data collection and management\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn this study, the data acquisition process depends on the electronic acquisition system. In the course of the study, researchers or participants can login the collection system through different ways. The required data will be collected according to the following case data collection schedule (Table 1). The participants mainly recorde the information of occupation/life characteristics, clinical symptoms, VAS and NDI data. The relevant data will be reviewed by the researchers and included in the medical records of the study. Since the risk is minimal, a formal data monitoring committee will not be required. Independent investigators will monitor data on a regular basis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.11. Statistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eStatistical analysis will use the statistical analysis software SAS9.4 for analysis and calculation. All statistical tests use two-sided test, the difference tested by P\u0026le;0.05 is statistically significant, the confidence interval is 95% credibility. The measurement data of different treatment groups will be statistically described by mean, standard deviation, median, minimum and maximum. The counting data of different treatment groups were statistically described by frequency (constituent ratio or incidence). In this study, the main efficacy index VAS score and secondary efficacy index NDI score are measurement data. In general, independent sample t-test is used for comparison between groups. If it does not satisfy the homogeneity of variance, independent sample corrected t-test is used. If it does not obey normal distribution, Wilcoxon rank sum test is used. At the same time, the covariance method is used to remove the confounding factors. The main efficacy analysis was based on FAS and the results of PPS analysis were provided.\u003c/p\u003e"},{"header":"3. Results","content":" \u003cp\u003eThe results of this trial will be published on the website of the China Clinical trial Registration Center and academic journals.\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eIn recent years, with the change of life style and work patterns, the incidence of CSR is getting higher and higher. according to incomplete statistics, the global incidence rate is about 4.9%, the pain caused by the disease has also brought an indirect economic burden about $335 billion to the society\u003csup\u003e[13]\u003c/sup\u003e. Modern medicine has described the pathogenesis of CSR in terms of anatomy and pathology. At present, it is generally believed that protrusion of nucleus pulposus, displacement of adjacent joints, hyperplasia of uncinate process joints and changes in physiological curvature of cervical vertebrae are the common causes of CSR\u003csup\u003e[14]\u003c/sup\u003e.These factors can lead to nerve root stimulation and compression, causing circulatory disorders and inflammatory reactions around the cervical vertebra, resulting in a series of root symptoms. Because CSR does not pose a threat to patients\u0026apos; lives,in addition, middle-aged patients are under great pressure in life, work and society, it is not easy to pay enough attention to it in the early stage, long-term neck stiffness, adverse activity and pain not only bring physical pain to patients, but also easily cause certain negative effects on patients\u0026apos; psychology, such as anxiety, depression and other bad emotions, which directly affect the quality of life of patients. TLQT is mainly made of 11 traditional Chinese medicines such as cloves, pepper, cinnamon, dried ginger, plus borneol, camphor and menthol. It has the effects of promoting blood circulation and dredging collaterals, dispelling cold and dehumidification, reducing swelling and relieving pain. It is one of the traditional methods of TCM in the treatment of chronic musculoskeletal diseases. In the past ten years, TLQT has been widely used in the treatment of cervical spondylosis, especially CSR. This kind of treatment is convenient, low-cost, and is deeply loved by the majority of CSR patients. However, so far there is no high-quality clinical evidence to support the claimed efficacy of TLQT in relieving pain and numbness in CSR patients. Therefore, the purpose of this clinical trial is to evaluate the efficacy and safety of TLQT in the treatment of CSR.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eTLQT=Tongluo Qutong plaster, CSR=cervical spondylotic radiculopathy, TCM=traditional Chinese medicine, VAS=visual analogue scale, NDI=neck disability index; NSAIDs=onsteroidal antiinflammatory drugs\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThis trial was approved by the Ethics Committee of the second people\u0026apos;s Hospital of Gansu Province(number GSSEY2021-YW010-02), and all participants voluntarily provided signed informed consent.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData sharing not applicable to this article as no datasets were generated or analyzed during the current study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by the National Natural Science Foundation of China (81860864, 82160911, and 82174412), Gansu Province Top Talent training and support Fund Project ([2021]02).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConceptualization: Hui Li, Yongli ZHAO\u003c/p\u003e\n\u003cp\u003eData curation: Hui Li, Yongli ZHAO\u003c/p\u003e\n\u003cp\u003eFormal analysis: Minzhen Wang, Jianguo Li\u003c/p\u003e\n\u003cp\u003eInvestigation: Demin Lin, Jianguo Li, Dingpeng Li\u003c/p\u003e\n\u003cp\u003eMethodology: Hui Li, Xingwen Xie\u003c/p\u003e\n\u003cp\u003eProject administration: Xingwen Xie,Ning Li\u003c/p\u003e\n\u003cp\u003eWriting - original draft: Hui Li, Xingwen Xie, Yongli ZHAO\u003c/p\u003e\n\u003cp\u003eWriting - review and editing: Xingwen Xie, Ning Li\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors have no conflicts of interest to disclose.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eLin T, Wang Z, Chen G, et al. Predictive Effect of Cervical Sagittal Parameters on Conservative Treatment of Single-Segment Cervical Spondylotic Radiculopathy. World Neurosurg. 2020;134:e1028-e1036.\u003c/li\u003e\n\u003cli\u003eHirai S, Kato S, Nakajima K, et al. Anatomical study of cervical intervertebral foramen in patients with cervical spondylotic radiculopathy. J Orthop Sci. 2021;26(1):86-91.\u003c/li\u003e\n\u003cli\u003eDai W, Wang X, Xie R, et al. Baduanjin exercise for cervical spondylotic radiculopathy: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(18):e0037s.\u003c/li\u003e\n\u003cli\u003eWang P, Zuo G, Du SQ, et al. Meta-analysis of the therapeutic effect of acupuncture and chiropractic on cervical spondylosis radiculopathy: A systematic review and meta-analysis protocol. Medicine (Baltimore). 2020;99(5):e18851.\u003c/li\u003e\n\u003cli\u003eYang F, Li WX, Liu Z, et al. Balance chiropractic therapy for cervical spondylotic radiculopathy: study protocol for a randomized controlled trial. Trials. 2016;17(1):513.\u003c/li\u003e\n\u003cli\u003eChildress MA, Becker BA. Nonoperative Management of Cervical Radiculopathy. Am Fam Physician. 2016;93(9):746-54.\u003c/li\u003e\n\u003cli\u003eKartha S, Weisshaar CL, Philips BH, et al. Pre-treatment with Meloxicam Prevents the Spinal Inflammation and Oxidative Stress in DRG Neurons that Accompany Painful Cervical Radiculopathy. Neuroscience. 2018;388:393-404.\u003c/li\u003e\n\u003cli\u003eDing X, Wu J, Shen Q, et al. Clinical control study of traditional Chinese medicine hot compress combined with traction in the treatment of cervical spondylotic radiculopathy: Study protocol. Medicine (Baltimore). 2021;100(4):e23880.\u003c/li\u003e\n\u003cli\u003eJIANG J C，WU J H，SHI C，et al.Clinical observation of Shi\u0026rsquo;s Tanyu Tongluo Decoction in the treatment of cervical spondylotic radiculopathy. Shanghai Journal of Traditional Chinese Medicine,2017;51(04):70-72.\u003c/li\u003e\n\u003cli\u003eJoyce CR, Zutshi DW, Hrubes V,et al. Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol. 1975;8(6):415-20.\u003c/li\u003e\n\u003cli\u003ePrice DD, McGrath PA, Rafii A, et al. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17(1):45-56.\u003c/li\u003e\n\u003cli\u003eSterling M, Rebbeck T. The Neck Disability Index (NDI). Aust J Physiother. 2005;51(4):271.\u003c/li\u003e\n\u003cli\u003eGaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715-24.\u003c/li\u003e\n\u003cli\u003eTruumees E, Herkowitz HN. Cervical spondylotic myelopathy and radiculopathy. Instr Course Lect. 2000;49:339-60.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Table 1","content":"\u003cp\u003e\u003cstrong\u003eTable\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;1 The schedule of enrolment, interventions, and assessments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cimg src=\"data:image/png;base64,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\" style=\"width: 551px;\" width=\"551\" height=\"633\"\u003e\u003c/strong\u003e\u003cbr\u003e\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Protocol, randomized controlled tria, cervical spondylotic radiculopathy, Tongluo Qutong plaster, diclofenac sodium plaster","lastPublishedDoi":"10.21203/rs.3.rs-2253409/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-2253409/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: Cervical spondylotic radiculopathy (CSR) is one of the most common diseases in clinic. Clinical symptoms such as neck pain and upper limb numbness are mainly caused by cervical degenerative changes and compression of cervical nerve roots. The incidence of CSR is the highest among all types of cervical spondylosis, accounting for about 60%~70%, seriously affecting the quality of life and work, causing huge economic negative to patients. Traditional Chinese medicine (TCM) has been definited efficacy and unique advantages in the treatment of CSR. Tongluo Qutong plaster (TLQT) is the most commonly used external drug in China in the treatment of CSR. It is effective for patients to improve neck pain, stiffness and numbness of both upper limbs, but there is a lack of high-quality clinical evidence to support it. The purpose of this study was to evaluate the efficacy and safety of TLQT in the treatment of CSR.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: This is a randomized, double-blind, parallel positive controlled, multi-center clinical trial. 240 patients who met the inclusion criteria were randomly divided into TLQT group and diclofenac sodium plaster group. The treatment period was 3 weeks. Follow-up will be conducted 12 weeks after intervention completion. The main observation index was visual analogue scale (VAS), and the secondary observation index was neck disability index (NDI) and TCM syndrome score. Safety observation indicators will include electrocardiogram, blood tests (including blood routine tests, liver and renal function), routine urine tests, and routine stool tests.The primary and secondary indicators will be performed at 0th, 3th, 7th, 21th and 84th day, and the safety indicators will be performed at 0th, 21th day.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e: This study will provide evidence for the efficacy and safety of TLQT in treating CSR patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTrial registration:\u003c/strong\u003eThis protocol has been registered in Chinese Clinical Trials Registry. Registration number: ChiCTR2200062271. Registered on 31 July 2022.\u003c/p\u003e","manuscriptTitle":"Efficacy and safety of Tong-luo Qu-tong plaster for cervical spondylotic radiculopathy: study protocol for a randomized, double-blind, parallel positive controlled, multicenter clinical trial","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-02-07 15:52:41","doi":"10.21203/rs.3.rs-2253409/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"25600b2a-c1cf-483b-8251-9181606f9513","owner":[],"postedDate":"February 7th, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2023-02-15T15:59:20+00:00","versionOfRecord":[],"versionCreatedAt":"2023-02-07 15:52:41","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-2253409","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-2253409","identity":"rs-2253409","version":["v1"]},"buildId":"7rjqhiLT3MXkJMwkYKINL","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}